What happened with TCMD today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Tactile Systems Technology, Inc. provides devices that let patients treat chronic conditions at home. Most revenue comes from its lymphedema products, used to manage swelling caused by impaired lymph drainage, including after cancer treatment. Its Flexitouch Plus system inflates and deflates chambers in a garment to move lymph fluid toward healthy regions of the body. Clinicians refer patients, and the company handles insurance claims, delivers the equipment directly and teaches patients how to use it. It earns from equipment sales and rentals, billing insurers and Medicare on patients’ behalf and collecting copayments and deductibles from patients.
A smaller business sells AffloVest, an airway-clearance vest for chronic respiratory conditions. Accredited durable medical equipment providers buy the product from the company, arrange prescriptions and reimbursement, and handle patient training and ongoing support. This business relies entirely on those providers rather than direct patient sales.
The main business depends on clinicians prescribing its devices and insurers covering them. Private insurance and other payers supply the largest share of revenue, with Medicare also a substantial source. Coverage varies by plan and is not universal; reimbursement also depends on supporting medical records. The company must maintain supplier accreditation and state licenses for its direct-sales model. Its marketed U.S. devices have FDA clearance for specific treatments, which limits the uses it may promote.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Tactile’s results hinge chiefly on reimbursed home lymphedema therapy, which accounts for 84% of revenue and faces principal manufacturing rivals Bio Compression Systems and Lympha Press USA.
Electromed’s SmartVest competes with Tactile Systems Technology’s AffloVest for prescribed home airway-clearance therapy: Electromed handles patient insurance claims directly, while Tactile sells through equipment providers that bill payers. Watch Electromed’s U.S. homecare revenue for competition in the airway-clearance business that supplied 16% of Tactile’s revenue in 2025.
Baxter International’s vests that oscillate the chest wall compete with Tactile Systems Technology’s AffloVest in airway clearance, but this market is only a small part of Baxter’s sales of healthcare products to hospitals and other care settings. Baxter’s respiratory-device news is therefore more relevant to AffloVest than its overall results.
Tactile Systems Technology, Inc. earningsThis company
Tactile Medical’s report will show whether sales of its lymphedema and airway-clearance devices are both growing, and whether payer coverage and authorization requirements are getting in the way of patients receiving them.
Read lymphedema and airway-clearance sales together, alongside what the company says about payer coverage and prior authorization. Growth in both would show expansion in its patient-facing lymphedema business and its airway-clearance business sold through equipment providers. If lymphedema grows but airway-clearance sales weaken, growth is more concentrated in the product line that supplies most revenue. Weakness in both would point to pressure on demand or on patients’ access to the devices.
Electromed, Inc. earningsELMD
Electromed’s report will show how demand and competition are changing in home airway-clearance therapy, the same market where Tactile Medical sells AffloVest through equipment providers.
Watch Electromed’s U.S. homecare revenue alongside Tactile Medical’s airway-clearance business, bearing in mind that their sales channels differ and the figures are not directly interchangeable. Growth would point to demand for home therapy, but also a potentially stronger SmartVest competitor. Weakness could reflect softer demand or Electromed’s own execution; it would not by itself show that Tactile is gaining share.
